Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 7/20 | 0.47 |
| ▸ | BRD1 | O95696 | 2/20 | 0.47 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11634100 | 0.76 | S100B (0.59) | ALDH1A1KDM4ETSHRTDP1BRPF1 | |
| SCHEMBL17576626 | 0.75 | BRPF1 (0.52) | ALDH1A1KDM4EBRPF1BRD1BRPF3 | |
| SCHEMBL16432414 | 0.75 | BRPF1 (0.52) | ALDH1A1KDM4EBRPF1BRD1BRPF3 | |
| SCHEMBL17576630 | 0.75 | S100B (0.58) | ALDH1A1KDM4ETSHRTDP1BRPF1 | |
| SCHEMBL30665881 | 0.75 | BRPF1 (0.52) | ALDH1A1KDM4EBRPF1BRD1BRPF3 | |
| SCHEMBL8359880 | 0.75 | BRPF1 (0.46) | ALDH1A1KDM4EBRPF1BRD1BRPF3 | |
| SCHEMBL1487621 | 0.72 | ALDH1A1 (0.71) | ALDH1A1KDM4ETSHRTDP1MAPT | |
| SCHEMBL21038794 | 0.70 | CYP2A6 (0.61) | ALDH1A1KDM4ETSHRBRPF1BRD1 | |
| SCHEMBL19231462 | 0.70 | CA2 (0.55) | ALDH1A1KDM4EBRPF1BRD9CA12 | |
| SCHEMBL3136850 | 0.70 | ALDH1A1 (0.90) | ALDH1A1KDM4ETSHRTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | claimed |
| JP-2002544128-A | — | — | 2002-12-24 | — | — | JP | claimed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | claimed |
| EP-1175417-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | WAKABAYASHI HIROAKI (JP) | 2002-05-02 | — | — | US | disclosed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6288225-B1 | Substituted benzolactam compounds as substance P antagonists | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| US-6180647-B1 | GASTROINTESTINAL DISORDERS; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | ALDH1A1 546/4885KDM4E 257/4885TSHR 1889/4885 |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | NPY1R, OPRM1, OPRL1 | ALDH1A1 901/4885KDM4E 1968/4885TSHR 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.